GU Cancers 2023 | The role of immune checkpoint inhibitors in mCRPC

Silke Gillessen, MD, Oncological Institute of Southern Switzerland, Bellinzona, Switzerland, discusses the role of immune checkpoint inhibitors (ICIs) in patients with prostate cancer and emphasises the excellent responses that patients with MSI-high disease can have compared to unselected patients. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.